20 results on '"Colomer R"'
Search Results
2. 1287P Immune T-cell subpopulations from the peripheral blood of non-small cell lung cancer patients are associated with the efficacy of anti-PD-1 immunotherapy
3. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) in human breast carcinoma cells
4. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
5. 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
6. 46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
7. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer
8. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
9. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin™) in breast cancer cells with Her-2/neu oncogene amplification
10. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain
11. Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells
12. The impact of primary tumor location in patients with resected colorectal liver metastasis
13. Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival
14. Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab
15. Could a systemic inflammation response index (SIRI) predict overall survival (OS) in metastatic pancreatic cancer (PC)?
16. P-281 - The impact of primary tumor location in patients with resected colorectal liver metastasis
17. P-164 - Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival
18. PD-016 - Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab
19. 113P - Could a systemic inflammation response index (SIRI) predict overall survival (OS) in metastatic pancreatic cancer (PC)?
20. Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.